Additionally, mutations in nRTKs contribute to the expression of the oncoprotein BCR–ABL, which has been associated with the development of hematological malignancies, including leukemia, lymphoma, and myeloma, through the STAT3 signaling pathway [204, 205]. Here, STAT3 is linked to hematologic disorder.